Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, commemorated its 50-year anniversary by awarding $150,000 in total grants to three organizations that share its goal to improve healthcare: The American Red Cross, the National Ovarian Cancer Coalition and Autism Speaks.
At a ceremony at the company’s flagship clinical laboratory in Teterboro, NJ, the company’s chairman, president and CEO Steve Rusckowski presented Health In Your Hands grants of $50,000 to representatives from each organization. Paul Brown, M.D., founder and former CEO of Quest’s predecessor company Metropolitan Pathology Laboratory, Inc. or MetPath, established in April, 1967, was also recognized at the event.
To view the multimedia release go to:
https://www.multivu.com/players/English/8080751-quest-diagnostics-50th-anniversary/
New science in molecular and genetic testing for breast, colon, and prostate cancer, as well as leukemia, will be among the special features at the College of American Pathologists’ annual scientific and education meeting, CAP’14—THE Pathologists’ Meeting, Sept. 7-10 at the Hyatt Regency in Chicago.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7270051-college-of-american-pathologists-cap-14-what-s-next-in-cancer-testing/
An international team of researchers led by Gerard D. Schellenberg, PhD, a member of the CurePSP Genetics Consortium and professor of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania, has identified three new genes that can increase the risk of people developing Progressive Supranuclear Palsy (PSP).
PSP is a rare neurodegenerative brain disease, similar to Parkinson’s disease, which causes severe disability by destroying parts of cells that allow the brain to function normally. While PSP has underlying biological similarities to Alzheimer’s disease, a disease which primarily affects memory, PSP impacts a person’s physical movement and bodily functions. PSP leads to progressive decline in patients — there is no known cause or cure.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/psp/49958/